Achillion Pharmaceuticals (NASDAQ:ACHN) Raised to “Hold” at BidaskClub

BidaskClub upgraded shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning, BidAskClub reports.

A number of other equities analysts also recently issued reports on ACHN. ValuEngine upgraded Achillion Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, July 23rd. Zacks Investment Research upgraded Achillion Pharmaceuticals from a sell rating to a hold rating and set a $3.00 price objective for the company in a research report on Tuesday, June 4th. Finally, Barclays downgraded Achillion Pharmaceuticals from an equal weight rating to an underweight rating and lowered their price objective for the stock from $5.00 to $2.50 in a research report on Friday, May 3rd. One analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $2.75.

Achillion Pharmaceuticals stock traded up $0.06 during trading hours on Tuesday, hitting $4.57. The stock had a trading volume of 31,157 shares, compared to its average volume of 2,407,824. The company has a market capitalization of $629.81 million, a PE ratio of -8.82 and a beta of 1.88. Achillion Pharmaceuticals has a one year low of $1.29 and a one year high of $5.03. The business has a 50 day moving average of $3.00.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.14). On average, sell-side analysts expect that Achillion Pharmaceuticals will post -0.59 EPS for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its stake in Achillion Pharmaceuticals by 1.5% during the fourth quarter. BlackRock Inc. now owns 12,101,177 shares of the biopharmaceutical company’s stock worth $19,241,000 after purchasing an additional 175,818 shares during the period. Geode Capital Management LLC grew its stake in Achillion Pharmaceuticals by 6.3% during the fourth quarter. Geode Capital Management LLC now owns 1,547,004 shares of the biopharmaceutical company’s stock worth $2,459,000 after purchasing an additional 91,346 shares during the period. Dimensional Fund Advisors LP grew its stake in Achillion Pharmaceuticals by 3.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 7,442,477 shares of the biopharmaceutical company’s stock worth $11,833,000 after purchasing an additional 259,762 shares during the period. Acadian Asset Management LLC grew its stake in Achillion Pharmaceuticals by 973.1% during the first quarter. Acadian Asset Management LLC now owns 278,573 shares of the biopharmaceutical company’s stock worth $825,000 after purchasing an additional 252,613 shares during the period. Finally, Virtu Financial LLC acquired a new stake in Achillion Pharmaceuticals during the first quarter worth approximately $33,000. Institutional investors own 79.30% of the company’s stock.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.

See Also: What is Depreciation?

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.